Fluorometholone

Evidence Level: L5

Predicted Indications: 9

Fluorometholone

Pharmacist Assessment Report

Fluorometholone: From Uveitis and Ocular Surface Inflammation to Postinfectious Vasculitis

One-Sentence Summary

Fluorometholone is a topical ophthalmic corticosteroid, originally used for uveitis, iritis, iridocyclitis, allergic and vernal conjunctivitis, and corneal ulcer. The TxGNN model predicts it may be effective for postinfectious vasculitis, but no clinical trials and no publications currently support this prediction, so it is a computational signal only.

Quick Overview

Item	Content
Original Indication	Uveitis and related ocular inflammatory conditions (iritis, iridocyclitis, atopic/vernal conjunctivitis, corneal ulcer)
Predicted New Indication	Postinfectious vasculitis
TxGNN Prediction Score	0.9991
Evidence Level	L5
India Market Status	Listed in a compiled Indian medicine price dataset (at least 20) – CDSCO approval status is not included in this data
Number of Listed Products	at least 20
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available. Based on known information, fluorometholone is a synthetic glucocorticoid that acts on the glucocorticoid receptor (NR3C1). Its efficacy in ocular inflammation is established, and mechanistically it may be applicable to immune-mediated inflammation elsewhere.

In theory, a glucocorticoid could suppress immune-mediated vasculitis. However, fluorometholone is formulated as a topical eye drop with minimal systemic exposure, so it is unlikely to reach concentrations relevant to a systemic vascular disease. The high score therefore comes from the TxGNN model (deep learning) and may reflect similarities the model learned between related diseases, not biological evidence.

Other predictions of note. The other nine predictions have no clinical trial support either. Three are close to the existing ocular indications and are better framed as research questions:

Glaucomatocyclitic crisis (score 0.9982): a recurrent anterior uveitis-like condition with raised intraocular pressure, where fluorometholone’s lower IOP risk is relevant.
Punctate epithelial keratoconjunctivitis (score 0.9989): the only prediction with any retrieved literature. It is the only one rated L4, but the two papers are indirect.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

No literature is available for postinfectious vasculitis. The only literature retrieved across the predictions relates to punctate epithelial keratoconjunctivitis (rank 6), and it is indirect:

PMID	Year	Type	Journal	Key Findings
34011737	2021	Review	Indian Journal of Ophthalmology	Characterises the sequelae of microsporidial keratoconjunctivitis and outlines its management
35128186	2021	Cohort	Journal of Current Ophthalmology	Uses anterior segment OCT to describe the phases of epidemic keratoconjunctivitis and the effect of topical steroid on its course

Neither paper appears to test fluorometholone specifically.

India Market Information

Twenty single-ingredient registrations are valid, and none are cancelled. All are ophthalmic eye drops or suspensions (5 ml packs). The data compiled for this report do not include approved indication text. Main authorizations:

Authorization Number	Product Name	Dosage Form	Approved Indication
84104	FML Liquifilm (Allergan India)	Ophthalmic suspension, 5 ml	Not listed
84883	Flosoft Eye Drop (Cipla)	Eye drop, 5 ml bottle	Not listed
87649	Flosef Eye Drop (Sun Pharmaceutical)	Eye drop, 5 ml	Not listed
88223	Flumace Eye Drop (Micro Labs)	Eye drop, 5 ml	Not listed
151524	New Biflace Eye Drop (Alembic)	Eye drop, 5 ml bottle	Not listed

Safety Considerations

Disease-level cautions (from the knowledge graph, not label text): Fluorometholone is flagged against several conditions, notably eye infections (herpes simplex keratitis, fungal and viral eye infections, ocular tuberculosis), open-angle glaucoma and ocular hypertension, diabetes mellitus and diabetic ketoacidosis, and porphyria. This matters for the infectious keratoconjunctivitis prediction, since corticosteroids can worsen infectious keratitis.
Drug Interactions: Twelve interaction records were found. Eleven are listed without a severity level: doxycycline, salbutamol, cyclosporine, acetaminophen, digoxin, brimonidine, cephalexin, alendronic acid, acyclovir, diazepam and fenofibrate. The twelfth is the pharmacological target record, the glucocorticoid receptor.

Please refer to the package insert for formal warnings and contraindications.

Conclusion and Next Steps

Decision: Hold

Rationale: The prediction for postinfectious vasculitis rests only on a model score. There are no trials or publications, and a topical eye drop has little systemic exposure. The ocular-adjacent predictions (glaucomatocyclitic crisis, lens-induced iridocyclitis, punctate epithelial keratoconjunctivitis) are more credible but also lack direct evidence.

To proceed, the following is needed:

Package insert warnings and contraindications for the Indian products
Detailed mechanism of action data
Direct clinical or literature evidence for fluorometholone in the predicted condition
A route and formulation assessment, because the topical ophthalmic form may not suit a systemic vascular disease
Consideration of prioritising the ocular-adjacent predictions as research questions, with intraocular pressure monitoring and infection screening
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.